Research during the two or three decades that followed this discovery, extended the geographic scope of Burkitt lymphoma from the high incidence of Sub-Saharan Africa, to North Africa, the Middle East [2] and South America as areas of intermediate incidence. A direct casual connection to nasopharyngeal carcinoma common in South East Asia was also discovered. In spite of the progress in understanding the geographic pathology of EBVrelated cancers, the oncogenic potential of EBV drew relatively little interest in the United States and Europe. However, when the HIV epidemic started to sweep these continents in the eighties, the role of EBV in lymphogenesis in immune compromised patients hit home, so to speak. HIV related, post transplant and post therapy associated EBV associated lymphoproliferative disorders were intensively investigated. It became clear that EBV, though remains dormant mostly in memory B cells escaping CD8+T cell elimination in immune competent individuals, it can be reactivated in some immune compromised patients. Not only Burkitt lymphoma was associated with EBV, but several other types of T, B, NK cells, plasmablastic and Hodgkin lymphomas [3]. EBV associated lymphoproliferative disorders are not uncommon in children, in the elderly, in therapy-related immune suppressed patients and in recent immigrants to the US.